Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A.

Blood Cancer J. 2015 Mar 20;5:e299. doi: 10.1038/bcj.2015.24.

2.

Targeting the BRAF V600E mutation in multiple myeloma.

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.

Cancer Discov. 2013 Aug;3(8):862-9. doi: 10.1158/2159-8290.CD-13-0014. Epub 2013 Apr 23.

3.

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.

Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM.

Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602.

4.

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A.

Endocr J. 2009;56(1):89-97. Epub 2008 Oct 8.

5.

The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?

Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L, Góźdź S.

Clin Endocrinol (Oxf). 2014 Jun;80(6):899-904. doi: 10.1111/cen.12386. Epub 2014 Jan 16.

PMID:
24354346
6.

Adult classical glioblastoma with a BRAF V600E mutation.

Takahashi Y, Akahane T, Sawada T, Ikeda H, Tempaku A, Yamauchi S, Nishihara H, Tanaka S, Nitta K, Ide W, Hashimoto I, Kamada H.

World J Surg Oncol. 2015 Mar 11;13:100. doi: 10.1186/s12957-015-0521-x.

7.

BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.

Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, Oh MH, Yang SH, Kim CJ.

Ann Surg Oncol. 2013 Mar;20(3):759-66. doi: 10.1245/s10434-012-2494-0. Epub 2012 Nov 21.

PMID:
23179992
8.

Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.

Brzeziańska E, Pastuszak-Lewandoska D, Wojciechowska K, Migdalska-Sek M, Cyniak-Magierska A, Nawrot E, Lewiński A.

Neuro Endocrinol Lett. 2007 Aug;28(4):351-9.

PMID:
17693984
9.

BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.

Ilie MI, Long-Mira E, Hofman V, Mouroux J, Vignaud JM, Gauchotte G, Begueret H, Merlio JP, Emile JF, Hébuterne X, Hofman P.

Pathology. 2014 Jun;46(4):311-5. doi: 10.1097/PAT.0000000000000113.

PMID:
24798160
10.

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F.

J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.

PMID:
18682506
11.

Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.

Wang W, Zhao W, Wang H, Teng X, Wang H, Chen X, Li Z, Yu X, Fahey TJ 3rd, Teng L.

Ann Surg Oncol. 2012 Jan;19(1):31-6. doi: 10.1245/s10434-011-2096-2. Epub 2011 Oct 27.

PMID:
22033631
12.

[Abnormalities of signal transduction molecules in multiple myeloma].

Sasaki M, Komatsu N.

Nihon Rinsho. 2015 Jan;73(1):62-8. Japanese.

PMID:
25626306
13.

Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.

Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L.

Anticancer Res. 2010 Sep;30(9):3267-72.

PMID:
20944096
14.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U.

J Clin Oncol. 2013 Sep 10;31(26):3205-11. doi: 10.1200/JCO.2013.49.8691. Epub 2013 Aug 5.

PMID:
23918947
15.

Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.

Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR, Park GS, Jung CK.

Endocr Relat Cancer. 2014;21(6):891-902. doi: 10.1530/ERC-14-0147. Epub 2014 Sep 29.

PMID:
25266729
16.

Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.

Méhes G, Irsai G, Bedekovics J, Beke L, Fazakas F, Rózsa T, Kiss C.

Am J Surg Pathol. 2014 Dec;38(12):1644-8. doi: 10.1097/PAS.0000000000000304.

PMID:
25118810
17.

BRAF V600E mutational status in pediatric thyroid cancer.

Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T, Grigsby PW.

Pediatr Blood Cancer. 2014 Jul;61(7):1168-72. doi: 10.1002/pbc.24935. Epub 2014 Mar 27.

PMID:
24677749
18.

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.

Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M.

Acta Neuropathol. 2012 Feb;123(2):223-33. doi: 10.1007/s00401-011-0887-y. Epub 2011 Oct 20.

PMID:
22012135
19.

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D.

Mod Pathol. 2014 Jul;27(7):1028-34. doi: 10.1038/modpathol.2013.206. Epub 2013 Dec 6.

20.

BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e65-8. doi: 10.1016/j.clml.2013.12.003. Epub 2013 Dec 17. No abstract available.

PMID:
24445188

Supplemental Content

Support Center